NASDAQ:BCYC Bicycle Therapeutics Q2 2026 Earnings Report $3.68 -0.05 (-1.21%) As of 03:37 PM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Bicycle Therapeutics EPS ResultsActual EPS-$0.72Consensus EPS -$0.58Beat/MissMissed by -$0.14One Year Ago EPSN/ABicycle Therapeutics Revenue ResultsActual Revenue$0.63 millionExpected Revenue$4.22 millionBeat/MissMissed by -$3.59 millionYoY Revenue GrowthN/ABicycle Therapeutics Announcement DetailsQuarterQ2 2026Date7/30/2026TimeBefore Market OpensConference Call DateThursday, July 30, 2026Conference Call Time7:00AM ETUpcoming EarningsBicycle Therapeutics' Q3 2026 earnings is estimated for Thursday, October 29, 2026, based on past reporting schedules, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Bicycle Therapeutics Earnings HeadlinesBicycle Therapeutics Ltd. ADRSeptember 24 at 2:58 PM | barrons.comCritical Contrast: Intellia Therapeutics (NASDAQ:NTLA) & Bicycle Therapeutics (NASDAQ:BCYC)September 21, 2026 | americanbankingnews.comIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially the reasons why we’re bombing the country.September 25 at 1:00 AM | Banyan Hill Publishing (Ad)RBC Capital Keeps Their Hold Rating on Bicycle Therapeutics (BCYC)August 5, 2026 | theglobeandmail.comVisa Inks $2.4 Billion Deal to Acquire Fraud Prevention Firm BioCatchAugust 3, 2026 | pymnts.comBicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial ResultsJuly 30, 2026 | finance.yahoo.comSee More Bicycle Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Bicycle Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bicycle Therapeutics and other key companies, straight to your email. Email Address About Bicycle TherapeuticsBicycle Therapeutics (NASDAQ:BCYC) plc (NASDAQ:BCYC) is a clinical-stage biopharmaceutical company developing medicines based on its proprietary Bicycle technology. The platform uses small, constrained peptides designed to bind selectively to biological targets, with the goal of combining the tissue penetration and manufacturing advantages of small molecules with the target specificity often associated with larger biologic medicines. The company’s research and development activities are focused primarily on oncology. Its pipeline includes Bicycle toxin conjugates, which are designed to deliver cancer-killing payloads to tumor cells, as well as Bicycle molecules intended to modulate immune targets and support other targeted therapeutic approaches. Bicycle Therapeutics has also pursued collaborations and partnered programs to apply its platform across a range of disease areas. Bicycle Therapeutics was founded in 2009 based on research originating at the University of Cambridge and maintains operations in Cambridge, England, and the United States. The company’s programs are developed for potential use in international markets, although most remain in clinical or preclinical development and are subject to regulatory review. Kevin Lee serves as the company’s president and chief executive officer.View Bicycle Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks3 Space Stocks to Watch as SpaceX Reshapes the Launch MarketOil May Be Stronger Than It Looks—And Diamondback Is on SaleBlackBerry Shifts Gears With Coretura Deal Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
